Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 74Neoplasm Metastasis 11Uveal Melanoma 7Skin Neoplasms 6Neoplasms 5Small Cell Lung Carcinoma 1Skin Diseases 1Sarcoma 1Recurrence 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Parathyroid Neoplasms 1Oligodendroglioma 1Melanoma, Cutaneous Malignant 1Melanoma Neoplasms 1Lung Neoplasms 1Kidney Neoplasms 1Gliosarcoma 1Glioma, Subependymal 1Glioma 1Glioblastoma 1Ependymoma 1Colonic Neoplasms 1Carcinoma 1Carcinoid Tumor 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1Advanced Melanoma 1

Interventions

binimetinib 2Aminolevulinic Acid 2methyl 5-aminolevulinate 1encorafenib 1Vemurafenib 1Radiotherapy 1Radiation 1Photochemotherapy 1Fluorouracil 1Floderm topical cream 1Equipment and Supplies 1Dacarbazine 1BF-200 ALA 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Skin Diseases × Dacarbazine × Dermatologic × Clear all
NCT01763164 2021-03-22

Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

Pfizer

Phase 3 Completed
402 enrolled 21 charts
Dermatologic

Melanoma, Neoplasm Metastasis, Skin Diseases, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡